

Correction

Correction: Schwach *et al.* More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug Conjugates. Frontiers in Bioscience-Landmark. 2022; 27: 240

Jonathan Schwach¹, Mustafa Abdellatif¹, Andreas Stengl^{1,*}

¹Ludwig-Maximilians-Universität München, Department of Biology II, Human Biology and Bioimaging, 82152 Planegg-Martinsried, Germany

*Correspondence: stengl@bio.lmu.de (Andreas Stengl)

Submitted: 3 March 2023 Accepted: 10 March 2023 Published: 26 April 2023

The authors wish to make the following corrections to this paper [1]:

1. the agent names of Loncastuximab tesirine and Tisotumab vedotin were switched, while the information of the remaining columns remains unaltered;
2. a spelling error in the commercial name of “Zynlonta” was corrected;
3. the stated producer of Kadcyla and Polivy specified to “Genentech” instead of “Roche”;
4. the indication of Loncastuximab tesirine has been specified to “DLBCL”.

The authors apologize for the inconvenience and state that the scientific conclusions of the paper remain unaffected.

References

- [1] Schwach J, Abdellatif M, Stengl A. More than Toxins—Current Prospects in Designing the Next Generation of Antibody Drug Conjugates. Frontiers in Bioscience-Landmark. 2022; 27: 240.

Original Table 1. FDA-approved antibody-drug conjugates.

Agent	Commercial Name	Target	Payload	Indications	Approval year
Gemtuzumab ozogamicin [3]	Mylotarg (Pfizer)	CD33	Calicheamicin	AML	2000/2017 (reapproved)
Brentuximab vedotin [4]	Adcetris (Seagen)	CD30	MMAE	HL & ALCL	2011
Ado-trastuzumab emtansine [5]	Kadcyla (Roche)	HER2	DM1	Breast cancer	2013
Inotuzumab ozogamicin [6]	Besponsa (Pfizer)	CD22	Calicheamicin	ALL	2017
Moxetumumab pasudotox [7]	Lumoxiti (AstraZeneca)	CD22	PE38	HCL	2018
Polatuzumab vedotin [8]	Polivy (Roche)	CD79B	MMAE	DLBCL	2019
Enfortumab vedotin [9]	Padcev (Seagen)	Nectin-4	MMAE	Urothelial carcinoma	2019
Fam-trastuzumab deruxtecan [10]	Enhertu (Daiichi Sankyo)	HER2	DXd	Breast cancer	2019
Sacituzumab govitecan [11]	Trodelvy (Immunomedics)	Trop-2	SN38	TNBC	2020
Belantamab mafodotin [12]	Blenrep (GlaxoSmithKline)	BCMA	MMAF	Multiple myeloma	2020
Tisotumab vedotin [13]	Zynlonta (ADC Therapeutics)	CD19	PBD Dimer	LBCL	2021
Loncastuximab tesirine [14]	Tivdak (Genmab/Seagen)	TF	MMAE	Cervical cancer	2021

AML, Acute Myeloid Leukemia; ALCL, Anaplastic Large-Cell Lymphoma; ALL, Acute Lymphocytic Leukemia; HCL, Hairy Cell Leukemia; HER2, Human Epidermal Growth Factor Receptor 2; CD, Cluster of Differentiation; DLBCL, Diffuse Large B-Cell Lymphoma; TNBC, Triple-Negative Breast Cancer; LBCL, Large B-Cell Lymphoma; BCMA, B-Cell Maturation Antigen; TF, Tissue Factor; MMAE, Monomethyl Auristatin E; MMAF, Monomethyl Auristatin F; PBD, Pyrrolbenzodiazepine.

Corrected Table 1. FDA-approved antibody-drug conjugates.

Agent	Commercial Name	Target	Payload	Indications	Approval Year
Gemtuzumab ozogamicin [3]	Mylotarg (Pfizer)	CD33	Calicheamicin	AML	2000/2017 (reapproved)
Brentuximab vedotin [4]	Adcetris (Seagen)	CD30	MMAE	HL & ALCL	2011
Ado-trastuzumab emtansine [5]	Kadcyla (Genentech)	HER2	DM1	Breast cancer	2013
Inotuzumab ozogamicin [6]	Besponsa (Pfizer)	CD22	Calicheamicin	ALL	2017
Moxetumumab pasudotox [7]	Lumoxiti (AstraZeneca)	CD22	PE38	HCL	2018
Polatuzumab vedotin [8]	Polivy (Genentech)	CD79B	MMAE	DLBCL	2019
Enfortumab vedotin [9]	Padcev (Seagen)	Nectin-4	MMAE	Urothelial carcinoma	2019
Fam-trastuzumab deruxtecan [10]	Enhertu (Daiichi Sankyo)	HER2	DXd	Breast cancer	2019
Sacituzumab govitecan [11]	Trodelvy (Immunomedics)	Trop-2	SN38	TNBC	2020
Belantamab mafodotin [12]	Blenrep (GlaxoSmithKline)	BCMA	MMAF	Multiple myeloma	2020
Loncastuximab tesirine [13]	Zynlonta (ADC Therapeutics)	CD19	PBD Dimer	DLBCL	2021
Tisotumab vedotin [14]	Tivdak (Genmab/Seagen)	TF	MMAE	Cervical cancer	2021

AML, Acute Myeloid Leukemia; ALCL, Anaplastic Large-Cell Lymphoma; ALL, Acute Lymphocytic Leukemia; HCL, Hairy Cell Leukemia; HER2, Human Epidermal Growth Factor Receptor 2; CD, Cluster of Differentiation; DLBCL, Diffuse Large B-Cell Lymphoma; TNBC, Triple-Negative Breast Cancer; LBCL, Large B-Cell Lymphoma; BCMA, B-Cell Maturation Antigen; TF, Tissue Factor; MMAE, Monomethyl Auristatin E; MMAF, Monomethyl Auristatin F; PBD, Pyrrolbenzodiazepine.

